Aug 032017

As a matter of disclosure : The author continues to be a current shareholder in the company: Sevion Theraputics Inc.

A recent article (; obtained on 8-3-2017), “Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million, Financing to support advancement of novel disease-modifying therapy targeting genetic diseases, including cystic fibrosis” began the following way:

“SAN DIEGO and REHOVOT, Israel, Aug. 2, 2017 /PRNewswire/ — Sevion Therapeutics, Inc. (SVON) and Eloxx Pharmaceuticals Ltd., a clinical stage company developing therapeutics for genetic diseases caused by nonsense mutations, announced today the closing of additional  US$8 million investment in Eloxx Pharmaceuticals led by LSP, a leading healthcare investor. The investment increases the total Series C financing raised by Eloxx to a total of US$38 million. By raising this amount, Eloxx finalized their Series C financing round.”


The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.

Louis DeCola, Jr.  © 2017                                    The Hygiology Post ®